Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

18.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeu ADR

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
From Summit Therapeutics Inc.
Via Business Wire
AlloVir, DigitalOcean And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. AlloVir, Inc. (NASDAQ: ALVR) shares dipped 24.1% to $3.74 in pre-market... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab Updated Data to be Featured at ASCO 2023
From Summit Therapeutics Inc.
Via Business Wire
Why Shares of Summit Therapeutics Slumped on Tuesday
The company's shares have been falling since it announced earnings late last week. 
Via The Motley Fool
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
From Summit Therapeutics Inc.
Via Business Wire
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
Why Shares of Summit Therapeutics Soared This Week
Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer. 
Via The Motley Fool
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)
From Summit Therapeutics Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
From Summit Therapeutics Inc.
Via Business Wire
Over $395M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks... 
Via Benzinga
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
From Summit Therapeutics Inc.
Via Business Wire
Macy's, Big Lots, Sprouts Farmers Market And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Workday, AdaptHealth And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. AdaptHealth Corp (NASDAQ: AHCO) shares dipped 18.3% to $17.95 in... 
Via Benzinga
Summit Therapeutics’ Rights Offering Nearing Expiration Date
From Summit Therapeutics Inc.
Via Business Wire
Acurx is Setting a High Bar for New Treatments in C. diff
A New Gold Standard for C. diff Therapy Could be in the Offing;  Next Data Release Expected in 2Q23 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! It's time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Why Alphabet And Amazon Are Trading Lower; Here Are 20 Stocks Moving Premarket
Gainers Nordstrom Inc. (NYSE: JWN) shares surged 29.56% to $27.39 in pre-market trading after activist investor Ryan Cohen took a stake in the company and announced he is planning to urge a board... 
Via Benzinga
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
From Summit Therapeutics Inc.
Via Business Wire
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
From Summit Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.